Literature DB >> 21653642

EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.

Hongyan Zhu, Urszula Dougherty, Victoria Robinson, Reba Mustafi, Joel Pekow, Sonia Kupfer, Yan Chun Li, John Hart, Kathleen Goss, Alessandro Fichera, Loren Joseph, Marc Bissonnette.   

Abstract

Epidermal growth factor receptors (EGFR) contribute to colonic tumorigenesis in experimental models of colon cancer. We previously showed that EGFR was also required for colonic tumor promotion by Western diet. The goal of this study was to identify EGFR-regulated microRNAs that contribute to diet-promoted colonic tumorigenesis. Murine colonic tumors from Egfr(wt) and hypomorphic Egfr(wa2) mice were screened using micro RNA (miRNA) arrays and miR-143 and miR-145 changes confirmed by Northern, real-time PCR, and in situ analysis. Rodent and human sporadic and ulcerative colitis (UC)-associated colon cancers were examined for miR-143 and miR-145. Effects of EGFR on miR-143 and miR-145 expression were assessed in murine and human colonic cells and their putative targets examined in vitro and in vivo. miR-143 and miR-145 were readily detected in normal colonocytes and comparable in Egfr(wt) and Egfr(wa2) mice. These miRNAs were downregulated in azoxymethane and inflammation-associated colonic tumors from Egfr(wt) mice but upregulated in Egfr(wa2) tumors. They were also reduced in human sporadic and UC colon cancers. EGFR signals suppressed miR-143 and miR-145 in human and murine colonic cells. Transfected miR-143 and miR-145 inhibited HCT116 cell growth in vitro and in vivo and downregulated G(1) regulators, K-Ras, MYC, CCND2, cdk6, and E2F3, putative or established targets of these miRNAs. miRNA targets Ras and MYC were increased in colonic tumors from Egfr(wt) but not Egfr(wa2) mice fed a Western diet. EGFR suppresses miR-143 and miR-145 in murine models of colon cancer. Furthermore, Western diet unmasks the tumor suppressor roles of these EGFR-regulated miRNAs. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653642      PMCID: PMC3819602          DOI: 10.1158/1541-7786.MCR-10-0531

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  68 in total

1.  Role of miR-143 targeting KRAS in colorectal tumorigenesis.

Authors:  X Chen; X Guo; H Zhang; Y Xiang; J Chen; Y Yin; X Cai; K Wang; G Wang; Y Ba; L Zhu; J Wang; R Yang; Y Zhang; Z Ren; K Zen; J Zhang; C-Y Zhang
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

2.  Nuclear overexpression of the E2F3 transcription factor in human lung cancer.

Authors:  Colin S Cooper; Andrew G Nicholson; Christopher Foster; Andrew Dodson; Sandra Edwards; Anne Fletcher; Toby Roe; Jeremy Clark; Anupam Joshi; Andrew Norman; Andrew Feber; Dongmei Lin; Yanning Gao; Janet Shipley; Shu-Jun Cheng
Journal:  Lung Cancer       Date:  2006-08-30       Impact factor: 5.705

Review 3.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

4.  MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  Oncol Rep       Date:  2006-10       Impact factor: 3.906

5.  Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.

Authors:  Alessandro Fichera; Nathaniel Little; Sujatha Jagadeeswaran; Urszula Dougherty; Amikar Sehdev; Reba Mustafi; Sonia Cerda; Weihua Yuan; Sharad Khare; Maria Tretiakova; Can Gong; Michael Tallerico; Greg Cohen; Loren Joseph; John Hart; Jerrold R Turner; Marc Bissonnette
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

6.  A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

Authors:  Ashwani Rajput; Alan P Koterba; Jeffrey I Kreisberg; Jason M Foster; James K V Willson; Michael G Brattain
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

7.  Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program.

Authors:  Sun Hee Rim; Laura Seeff; Faruque Ahmed; Jessica B King; Steven S Coughlin
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

Review 8.  MicroRNA expression and function in cancer.

Authors:  Ramiro Garzon; Muller Fabbri; Amelia Cimmino; George A Calin; Carlo M Croce
Journal:  Trends Mol Med       Date:  2006-10-30       Impact factor: 11.951

9.  Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.

Authors:  William C S Cho; Andrew S C Chow; Joseph S K Au
Journal:  Eur J Cancer       Date:  2009-06-01       Impact factor: 9.162

10.  MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells.

Authors:  Na Xu; Thales Papagiannakopoulos; Guangjin Pan; James A Thomson; Kenneth S Kosik
Journal:  Cell       Date:  2009-04-30       Impact factor: 41.582

View more
  64 in total

Review 1.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 2.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.

Authors:  Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration.

Authors:  Raghu R Chivukula; Guanglu Shi; Asha Acharya; Eric W Mills; Lauren R Zeitels; Joselin L Anandam; Abier A Abdelnaby; Glen C Balch; John C Mansour; Adam C Yopp; Anirban Maitra; Joshua T Mendell
Journal:  Cell       Date:  2014-05-22       Impact factor: 41.582

4.  ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer.

Authors:  Reba Mustafi; Urszula Dougherty; Devkumar Mustafi; Fatma Ayaloglu-Butun; Michelle Fletcher; Sarbani Adhikari; Farhana Sadiq; Katherine Meckel; Haider I Haider; Abdurahman Khalil; Joel Pekow; Vani Konda; Loren Joseph; John Hart; Alessandro Fichera; Yan Chun Li; Marc Bissonnette
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

Review 5.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

Review 6.  Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention.

Authors:  Baldeep Pabla; Marc Bissonnette; Vani J Konda
Journal:  World J Clin Oncol       Date:  2015-10-10

7.  Identification and characterization of progesterone- and estrogen-regulated MicroRNAs in mouse endometrial epithelial cells.

Authors:  Dong-zhi Yuan; Lin-lin Yu; Ting Qu; Shi-mao Zhang; You-bo Zhao; Jun-li Pan; Qian Xu; Ya-Ping He; Jin-hu Zhang; Li-min Yue
Journal:  Reprod Sci       Date:  2014-06-12       Impact factor: 3.060

Review 8.  MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Authors:  Xiang Li; Jing Nie; Qian Mei; Wei-Dong Han
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

9.  MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells.

Authors:  Zhigang Hu; Wen-Jun Shen; Fredric B Kraemer; Salman Azhar
Journal:  Mol Cell Biol       Date:  2012-10-08       Impact factor: 4.272

10.  Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1.

Authors:  Sripathi M Sureban; Dongfeng Qu; Courtney W Houchen
Journal:  Curr Pharmacol Rep       Date:  2015-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.